These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 21519907

  • 21. An update on tardive dyskinesia: from phenomenology to treatment.
    Waln O, Jankovic J.
    Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 23858394
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Oxidative mechanisms and tardive dyskinesia.
    Lohr JB, Kuczenski R, Niculescu AB.
    CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
    [Abstract] [Full Text] [Related]

  • 25. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.
    Barnes TR, McPhillips MA.
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S49-57. PubMed ID: 9690971
    [Abstract] [Full Text] [Related]

  • 26. Levetiracetam in tardive dyskinesia.
    Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N, Di Rosa AE, Morgante L.
    Clin Neuropharmacol; 2006 Mar; 29(5):265-8. PubMed ID: 16960471
    [Abstract] [Full Text] [Related]

  • 27. Levetiracetam in tardive dyskinesia: an open label study.
    Konitsiotis S, Pappa S, Mantas C, Mavreas V.
    Mov Disord; 2006 Aug; 21(8):1219-21. PubMed ID: 16637037
    [Abstract] [Full Text] [Related]

  • 28. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
    Tarsy D, Baldessarini RJ.
    Mov Disord; 2006 May; 21(5):589-98. PubMed ID: 16532448
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives.
    Kulkarni SK, Naidu PS.
    Drugs Today (Barc); 2003 Jan; 39(1):19-49. PubMed ID: 12669107
    [Abstract] [Full Text] [Related]

  • 34. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia.
    Sachdev P, Hume F, Toohey P, Doutney C.
    Acta Psychiatr Scand; 1996 Jun; 93(6):451-9. PubMed ID: 8831862
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
    Pardis P, Remington G, Panda R, Lemez M, Agid O.
    J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.